Advertisement

Topics

bluebird bio’s stock tanks after report of serious toxicity in sickle cell patient

15:19 EST 3 Dec 2018 | MedCity News

genomics

A company analysis deemed the patient’s myelodysplastic syndrome was unrelated to LentiGlobin, but a news report indicated it may have stemmed from the conditioning regimen used in the trial.

Original Article: bluebird bio’s stock tanks after report of serious toxicity in sickle cell patient

NEXT ARTICLE

More From BioPortfolio on "bluebird bio’s stock tanks after report of serious toxicity in sickle cell patient"

Advertisement
Quick Search
Advertisement
Advertisement